FXR 5 Tablet contains Obeticholic acid 5mg, a potent farnesoid X receptor (FXR) agonist used primarily in the treatment of certain liver diseases. Obeticholic acid works by activating FXR, a nuclear receptor involved in regulating bile acid synthesis, lipid metabolism, and glucose homeostasis. This mechanism helps reduce liver inflammation and fibrosis, making FXR 5 effective in managing conditions such as primary biliary cholangitis (PBC), especially in patients who have an inadequate response or intolerance to ursodeoxycholic acid. By modulating bile acid pathways, FXR 5 improves liver function tests and slows disease progression. The tablet is typically administered orally, with dosage tailored by a healthcare professional based on the patient’s condition and response to therapy. Common side effects may include pruritus, fatigue, and gastrointestinal discomfort, but these are generally manageable. FXR 5 should be used under medical supervision, with regular monitoring of liver function and lipid profiles to ensure safety and efficacy. It is contraindicated in patients with complete biliary obstruction and should be used cautiously in those with advanced liver disease. Overall, FXR 5 Tablet offers a targeted therapeutic option for improving liver health and quality of life in patients with chronic cholestatic liver disorders.